Treatment and prevention in herpes zoster;Tratamiento y prevención del herpes zoster

Medicina Clinica

Volumn 125, Issue 6, 2005, Pages 215-220

  García, Amaro ^a,c   Guerra Tapia, Aurora ^b   Torregrosa, Jose Vicente ^c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CAPSAICIN; EMLA; FAMCICLOVIR; FENTANYL; FOSCARNET; GABAPENTIN; LIDOCAINE; METHYLPREDNISOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR;

DISEASE PREDISPOSITION; GENOTYPE; HERPES ZOSTER; HUMAN; POSTHERPETIC NEURALGIA; REVIEW; VARICELLA ZOSTER VIRUS;

EID: 23844462429     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13077377     Document Type: Article

References (65)

1. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Viral disease. En: Fitzpatrick's, editor. Dermatology in general medicine. 6th ed. Ohio: The McGraw-Hill Companies, Inc.; 2003. p. 2070.
2. Liesegang T. Varicella zoster viral disease. Mayo Clin Proc. 1999;74:983-98.
3. Dworkin RH, Schmader KE. Epidemiology and natural history of herpes zoster and postherpetic neuralgia. En: Watson CPN, Gershon AA, editors. Herpes zoster and postherpetic neuralgia. 2nd ed. New York: Elsevier Press; 2001. p. 39-64.
4. Wood MJ. Treatment of herpes zoster in the elderly. Herpes. 1998;5:60-3.
5. Kinchington PR, Turse SE. Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody. Neurology. 1995; 45:S13-4.
6. Santos RA, Padilla JA, Hatfield C, Grose C. Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology. 1998;249:21-31.
7. Loparev VN, Gonzalez A, Deleon-Carnes M, Tipples G, Fickenscher H, Torfason EG, et al. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol. 2004;78:8349-58.
8. Tipples GA, Stephens GM, Sherlock C, Bowler M, Hoy B, Cook D, et al. New variant of varicella-zoster virus. Emerg Infect Dis. 2002;8:1504-5.
9. Gil A, San-Martín M, Carrasco P, González A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004;22:3947-51.
10. Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population- based study. Pediatrics. 1985;76:512-7.
11. Di Luzio Paparatti U, Arpinelli F, Visona G. Herpes zoster and its complications in Italy: an observational survey. J Infect. 1999;38:116-20.
12. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. 2003;70:S9-14.
13. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine. 1982;61:310-6.
14. Gnann JW, Whitley RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991;18 Suppl A:317-29.
15. Schmander KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-4.
16. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157:1217-24.
17. Solomon AR. New diagnostic tests for herpes simplex and varicella zoster infections. J Am Acad Dermatol. 1988;18(1 Pt 2):218-21.
18. Dahl H, Marcoccia J, Linde A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol. 1997;35:347-9.
19. Rubben A, Baron JM, Grussendorf-Conen EI. Routine detection of herpes simplex virus and varicella zoster virus by polymerase chain reaction reveals that initial herpes zoster is frequently misdiagnosed as herpes simplex. Br J Dermatol. 1997;137:259-61.
20. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340-6.
21. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003;326:748-50.
22. Johnson R, Patrick D. Improving the management of varicella, herpes zoster and zoster-associated pain. Recommendations from the IHMF Management Strategies Workshop; 2001 March 6-7. Disponible en: http://www.ihmf.org/Library/ monograph/m_11.pdf
23. Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999;340:1255-68.
24. Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, et al. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988;85 Suppl 2A:84-9.
25. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J. 1989;102:93-5.
26. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J. 1986;293:1529-32.
27. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22:341-7.
28. Bleyzac N, Barou P, Massenavette B, Contamin B, Maire P, Berthier JC, et al. Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis. Ther Drug Monit. 1999;21:520-5.
29. Leikin JB, Shicker L, Orlowski J, Blair AT, McAllister K. Hemodialysis removal of acyclovir. Vet Hum Toxicol. 1995;37:233-4.
30. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546-53.
31. Fármacos para las infecciones virales. The medical setter on drugs and therapeutics. En: Albrecht MA. Treatment of genital herpes simples virus infection. 2002. Vol. XXIV. p. 19-26. Disponible en: http//www.uptodate.com
32. Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Arch Intern Med. 2000;160:1705-6.
33. Giménez F, Foeillet E, Bourdon O, Weller S, Garret C, Bidault R, et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet. 2004;43:685-92.
34. Izzedina H, Mercadal L, Aymard G, Launay-Vacher V, Martinez V, Issad B, et al. Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. Am J Nephrol. 2001;21:162-4.
35. Stathoulopoulou F, Dhillon S, Thodis, H, Stathakis C, Vargemezis V. Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. Nephron. 2002;91:164-6.
36. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 9-(4-hydroxy-3-hydroxymethylbut-l-yl) guanine; penciclovir. Antimicrob Agents Chemother. 1989;33:1765-73.
37. Lin P, Torres G, Tyring SK. Changing paradigms in dermatology: antivirals in dermatology. Clin Dermatol. 2003;21:426-46.
38. Degreef H, Group FHZCS. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994;4:241-6.
39. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123:89-96.
40. Ashton R. Efficacy of administration of famciclovir, once and twice daily famciclovir for the treatment of acute herpes zoster (abstr W107). First European Congress of chemotherapy; 1996 May 14-17; Glasgow.
41. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9:863-9.
42. Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A, et al. Once, twice, or three times daily famciclovir compared with acyclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol. 2004;29:248-53.
43. Wassilew SW, Stubinski BM, Koch I, Schumacker K, Capriati A. Brivudin compared to famciclovir for improved therapy of herpes zoster: effects on acute disease and postherpetic neuralgia. Int J Antimicrob Agents. 2002;19 Suppl 1:S22.
44. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL; Colaborative Famciclovir Immunocompromised Study Group. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001;19:13-22.
45. Engst R, Schiewe U, Höbel W, Machka K, Meister W. Famciclovir in treatment of acute herpes zoster: results of two post-marketing surveillance studies in Germany. Acta Dermato-Venereologica. 2001;81:59-60.
46. Boike SC, Pue MA, Freed ML, Audet PR, Fairless A, Ilson BE, et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol. 1994;55:418-26.
47. Shigeta S, Yokota T, De Clercq E. Therapy of varicella-zoster virus infection - mechanism of action of (E)-5-(2-bromovinyl)-2′-deoxyuridine. Antiviral Res. 1985;Suppl 1:35-44.
48. Wassilew SW, Wutzler P; Brivddin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res. 2003;59:49-56.
49. Ficha técnica de Nervinex, Guidotti Farma.
50. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1989;40:213-85.
51. Snoeck R, Andrei G, Clercq ED. Novel agents for the therapy of varicella-zoster virus infections. Expert Opin Investig Drugs. 2000;9:1743-51.
52. Brown TJ, Vander Straten M, Tyring SK. Antiviral agents. Dermatol Clin. 2001;19:23-34.
53. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896-900.
54. Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376-83.
55. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain. 2000;87:121-9.
56. Dworkin RH, Perkins FM, Nagasako EM. Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin J Pain. 2000;16 Suppl 2:S90-100.
57. Kanazi GE, Johnson RW, Dworkin RH. Treatment of postherpetic neuralgia: an update. Drugs. 2000;59:1113-26.
58. Johnson RW. Herpes zoster in the immunocompetent patient: management of post herpetic neuralgia. Herpes. 2003;10:38-45.
59. Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, Yodono M, et al. Intrathecal methyl prednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000;343:1514-9.
60. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2:1288-90.
61. Campins M, Moraga FA. ¿Es eficaz la vacuna de la varicela? Med Clin (Barc). 2002;119:571-3.
62. Asensi F, Otero MC, Pérez D, San Miguel MJ. Indicaciones actuales de la vacuna antivaricela. An Pediatr. 2003;59 Supl 1:63-6.
63. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-11.
64. Vázquez M. Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine. Curr Opin Pediatr. 2004; 16:80-4.
65. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125:651-69.